You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Developing a selective TRPC3 ion channel inhibitor for epilepsy treatment

    SBC: SEAK Therapeutics, LLC            Topic: 106

    Project SummaryEpilepsy is one of the most common brain disorders. Current drugs have limited efficacy. Identifying new targeted drugs that can be used as safer, more effective therapies is in urgent unmet need. Selective inhibition of the transient receptor potential canonical 3 (TRPC3) emerges as a novel strategy to impede epilepsy. However, the currently best selective TRPC3 inhibitor, Pyr3, ha ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Vitiligo topical treatment applying a potent, highly selective MC1R agonist

    SBC: MC1R VENTURES LLC            Topic: NIAMS

    PROJECT SUMMARY Vitiligo is the most common acquired hypopigmentary disorder that afflicts 0.5-2% of the world population, from all ethnicities and skin color. It is characterized by loss of melanocytes, which is often progressive, resulting in depigmented skin lesions. Vitiligo can be segmental (5-16% of all cases) or most commonly, non-segmental. It is a disease of young adults, as 25% of all no ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Inter-alpha Inhibitors in Experimental Necrotizing Enterocolitis

    SBC: PROTHERA BIOLOGICS, INC.            Topic: NICHD

    Necrotizing enterocolitis (NEC) is a devastating acute inflammatory condition of the gastrointestinal tract resulting in intestinal necrosis, systemic sepsis and multi-system organ failure found mostly in infants born prematurely. Despite modern medical advances in the past decade, the etiology remains elusive and morbidity and mortality are still unacceptably high. It has been concluded that the ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Optimizing Small Molecule Mechanomimetics to Treat Age-related Osteoporosis.

    SBC: OAK RIDGE THERAPEUTIC DISCOVERY LLC            Topic: NIA

    Abstract There is an unmet need to develop treatments for senile osteoporosis, a disorder characterized by an age-related reciprocal decrease in osteogenesis and increase in bone marrow fat. Senile osteoporosis resembles disuse osteopenia, suggesting its pathogenesis involves impaired bone mechanosensing. We discovered that the polycystin heterotrimeric complex (1PC1+3PC2) functions as a mechanose ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. ETAware: Continuous monitoring of the functional impact of essential tremor

    SBC: Great Lakes Neurotechnologies Inc.            Topic: NIA

    SummaryThe objective is to design and clinically assess ETAware, an adaptive, wearable system to monitor the impact of tremor on activities of daily living (ADL) for the evaluation and optimization of therapeutic interventions in patients with essential tremor (ET) as there is currently no technology that can assess the functional impact of tremor on ADL. ETAware will focus on ET, the most common ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. ADVANCED COMPREHENSIVE MAGNETIC RESONANCE SOLUTION FOR THE NONINVASIVE CHARACTERIZATION OF HIGH RESOLUTION METABOLIC BIOMARKERS OF RISK IN PATIENTS WITH ALZHEIMER'S DISEASE AND DEMENTIA

    SBC: ADVANCED IMAGING RESEARCH, INC.            Topic: R

    NIH SBIR Fast-Track, PAS-22-196 Advanced Comprehensive Magnetic Resonance Solution for the Non Invasive Characterization of No Clinical Trials High Resolution Metabolic Biomarkers of Risk in Patients with Alzheimer’s Disease and Dementia Project Summary This project addresses the Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) Initiative of the National Institute o ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Novel Adipose Targeted Gene Therapy for Lipodystrophy

    SBC: ZVELT THERAPEUTICS INC.            Topic: NIDDK

    PROJECT SUMMARY Lipodystrophy includes a heterogeneous group of disorders that are characterized by abnormal or degenerative conditions of the adipose tissue. This rare and often underdiagnosed condition can be partial/localized or generalized and is generally associated with metabolic disorders such as insulin resistance, diabetes, hyperglycemia, hyperlipidemia, and other severe conditions. Lipod ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Real-time Multimodal Diffuse Reflectance and Polarization Imaging Based Nerve Identification in Surgical Field of View

    SBC: YAYA SCIENTIFIC LLC            Topic: NIBIB

    PROJECT SUMMARY We propose to develop a novel non-contact, label-free multimodality imager that provides real-time intraoperative identification of nerves within the surgical field-of-view to facilitate the prevention of unintended nerve damage (termed iatrogenic nerve injury) during surgical procedures, as they are a major source of postsurgical complications, e.g., chronic pain. In the United St ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Inter-alpha Inhibitors in Hypoxic-Ischemic Brain Injury

    SBC: PROTHERA BIOLOGICS, INC.            Topic: 105

    Perinatal brain injury resulting in mental retardation and cerebral palsy is the most severe disability in children and affects 40-148 in preterm and 1–2/1000 in full term infants. This places a huge burden on society, emphasizing the critical need for improved prevention/treatment strategies to decrease perinatal brain injury. Hypothermia (HT) is the only FDA approved therapy to attenuate brain ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Development of CA-IL-12 for Triple Negative Breast Cancer

    SBC: CYTONUS THERAPEUTICS INC            Topic: 102

    Most cancer patients die as a result of metastatic disease and our inability to effectively deliver therapeutic drugs into the anatomical niches where cancer cells thrive. Thus, there is a major unmet need to develop therapeutic strategies that effectively target cancer cells in the local tumor microenvironment (TME) while minimizing peripheral toxicity. Cytonus Therapeutics and UCSD Moores Cancer ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government